View Older Stories View More Recent Stories

Sep 4, 2022 06:05PM New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
Aug 29, 2022 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Aug 29, 2022 08:32AM Gilead Sciences (GILD) Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types
Aug 29, 2022 08:30AM Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
Aug 22, 2022 05:42AM Gilead Sciences (GILD) Granted Approval of Sunlenca in EU
Aug 22, 2022 01:00AM Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
Aug 17, 2022 11:00AM Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
Aug 16, 2022 05:55AM Gilead Sciences (GILD) Acquires Remaining Worldwide Rights of Trodelvy
Aug 15, 2022 07:15PM Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
Aug 15, 2022 08:33AM Gilead Sciences (GILD) Announces Trodelvy Significantly Improves OS in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
Aug 15, 2022 08:30AM Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
Aug 9, 2022 10:00AM Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
Aug 4, 2022 08:03AM Gilead Sciences (GILD) Acquires MiroBio
Aug 4, 2022 08:00AM Gilead Sciences to Acquire MiroBio
Jul 28, 2022 01:30PM Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
Jul 27, 2022 07:00AM AlloVir Announces $126.6 Million Registered Direct Offering
Jul 22, 2022 09:42AM Gilead Sciences (GILD) Announces Kite’s CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia
Jul 22, 2022 09:42AM Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
Jul 22, 2022 07:06AM Gilead Sciences (GILD) Receives Positive CHMP Opinion Recommending Veklury Receive Full Marketing Authorization
Jul 22, 2022 07:06AM CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
Jul 21, 2022 08:30AM Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
Jul 20, 2022 12:30PM Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
Jul 19, 2022 09:00AM Gilead Sciences (GILD) Enters Procurement Agreement with the European Commission for Veklury
Jul 19, 2022 09:00AM Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
Jul 12, 2022 04:05PM Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
Jul 12, 2022 08:30AM Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
Jun 28, 2022 06:02AM Gilead Sciences (GILD) Granted EU Approval for Yescarta for Treatment of Relapsed or Refractory Follicular Lymphoma
Jun 28, 2022 06:00AM Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
Jun 27, 2022 04:30PM Gilead Sciences (GILD) Resubmits NDA to FDA for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
Jun 27, 2022 04:30PM Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
Jun 27, 2022 09:00AM Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
Jun 24, 2022 08:00AM Gilead Sciences (GILD) Announces Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Jun 24, 2022 08:00AM Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Jun 23, 2022 08:31AM Gilead Sciences (GILD) Announces Treatment With Hepcludex Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Jun 23, 2022 08:30AM Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Jun 21, 2022 09:00AM Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
Jun 6, 2022 09:00AM Gilead Sciences (GILD) Reports Final Data From Phase 3 ASCENT Study Showing Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Jun 6, 2022 09:00AM Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Jun 6, 2022 05:51AM Gilead Sciences (GILD) Reports Tecartus Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up
Jun 4, 2022 04:00PM Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell
Jun 4, 2022 01:38PM Gilead Sciences (GILD) Reports Trodelvy Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 4, 2022 09:00AM Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphom
Jun 4, 2022 08:00AM Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
Jun 3, 2022 04:00PM Gilead Sciences's (GILD) Kite Announces Yescarta CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Jun 3, 2022 04:00PM Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Jun 2, 2022 09:00AM Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
May 19, 2022 01:30PM Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
May 17, 2022 04:30PM Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
May 16, 2022 04:10PM Gilead Sciences (GILD) Announces FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
May 16, 2022 04:10PM FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
View More Recent Stories View Older Stories